**Core tip:** This work is a contribution to the current knowledge of hepatic encephalopathy (HE) and shows new important data about aspect less studied, as ammonia effect inducing morphological ultrastructural damage in skeletal muscle and gut. These alterations were observed in a Minimal HE model without liver damage, which suggests that the damage caused by ammonia may occur before liver failure.

INTRODUCTION
============

Hepatic encephalopathy (HE) is a neuropsychiatric complex syndrome, ranging from subtle behavioral abnormalities to deep coma and death\[[@B1]\]. HE is potentially reversible and emerges as the major complication of acute or chronic liver failure (ALF, CLF)\[[@B2]\]. RF Butterworth in his recent review\[[@B3]\] stressed that brain edema that accompanies ALF is the primarily cytotoxic phenomena, and moreover, this correlates with alterations in expression of genes coding for key astrocytic proteins\[[@B4]\].

There are clinical conditions with a greater chance of developing cerebral edema, such as deep encephalopathy, hyperacute (ALF-acetaminophen induced) liver failure, severe hyperammonemia, younger age and infection\[[@B5]\]. A controversial area is to establish conclusively whether the percentage of deaths could be attributable to a cerebral edema or to a multiple organ failure. Clemmensen reported in patients with ALF a correlation between arterial ammonemia and brain herniation. Therefore, hyperammonemia in ALF is a key factor for the understanding the pathophysiology of ALF\[[@B3]\].

On the other hand, situation changes drastically in CLF. In the first diagnostic stage, patients studied with conventional clinical assessments could be considered normal from a neurological view, but its evaluation with neuro-psychometric tests, flicker, *etc*., could possibly staged as a subclinical HE, or "minimal hepatic encephalopathy" (MHE)\[[@B6],[@B7]\].

MHE may be persistent or intermittent (spontaneous or precipitated for different circumstances), but the data indicate that between two clinical episodes, patients do not return to their previous neurological status\[[@B8]\]. It becomes necessary to understand HE pathophysiology in early stages, in its big bang, to establish the mechanism that triggers HE and subsequent neurological consequences.

As seen in Figure [1](#F1){ref-type="fig"}, many paths, molecules, and biological unbalanced equations are involved\[[@B1]\]. The first reference of a patient with chronic liver disease, most likely associated with HE, was documented by G. Morgagni in 1765. Ammonia stands on the scene of HE from the very beginning, and is considered the main culprit. However, no one could give a judgment without risk of injustice. Thus in CLF, the defendant, who is supposed to be under trial in this editorial is ammonia\[[@B9]\]. Although, there are others implicated in HE pathophysiology, such as edema and manganese, it is not possible, to explain HE without the implication of hyperammonemia.
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This publication is an approach to MHE, providing in brief some new data that are usually not taken into account, in an attempt to reveal the initial steps of the HE pathophysiology. Also it is suggested that research should be strongly directed to MHE, in order to seek for still unknown mechanisms.

The diagnosis of MHE is still a challenge, and some experimental models, such as the portal vein ligation (PVL), develops two basic characteristics of CLF in its early stages, mild hyperammonemia and MHE\[[@B10]\], thus being a useful tool for the study of MHE pathophysiology and how it finally develops HE without liver disease\[[@B11]\].

Despite the difficulties, it is very important the early diagnose of MHE, because the experimental models of MHE are teaching that there are significant pathological changes, which should be take into account at this stage. We will not discuss here the recognized features such as Alzheimer type II Astrocytes, an important morphological feature of HE\[[@B12]\]. This work will take into account some of the roads less traveled about MHE, skeletal muscle and intestine, which is the major consumer of glutamine (GLN) and the major ammonia producer\[[@B13]\]. Skeletal muscle becomes the main mass of tissue able to metabolize ammonia when liver failure is established and its capacity of ammonia detoxification is reduced drastically. In this way, perhaps we could reconsider that MHE is not so minimal.

SKELETAL MUSCLE AND MHE
=======================

Sarcopenia is a common feature of cirrhosis, and the loss of muscle mass and function contributes to its morbidity and mortality. Its prevalence in patients with cirrhosis is estimated to be 40%-70%, well correlated with HE\[[@B14],[@B15]\].

The skeletal muscle damage in cirrhosis is underestimated by physicians although its prevalence is higher than other gastrointestinal complications. Perhaps the poorly understanding of its pathogenesis, the not so well established diagnostic criteria and that none of the proposed treatment options have been well explored in randomized clinical trials, helps to this clinical conduct.

Patients with chronic liver disease (CLD) concomitantly decrease the capability of detoxification of ammonia to urea, shifts ammonia metabolic pathway to the muscular system, to the astrocyte in the central nervous system (CNS) and to the kidney. In the case of liver failure, the first two tissues turn into main organs in detoxifying ammonia. Skeletal muscle tissue, due to its large size, becomes the main ammonia detoxifying organ\[[@B16]\]. In hypoproteic diet which is a very common procedure in treating patients with liver failure, muscular glutamine-synthase becomes an important enzyme in this metabolism, although a normal proteic diet may be metabolically more adequate and can be safely administered to the cirrhotic patient\[[@B17]\]. But hypoproteic diet may decrease the muscular mass and therefore the ammonia detoxifying ability, therefore could be a controversial procedure in patients with liver disease and established hyperammonemia and MHE. On the other side, recently, diet supplementation with branched chain amino acids shown to decrease MHE and to increase muscle mass\[[@B18]\]. This should be balanced because the astrocytic enzyme glutamate synthetase (GS) works at the limit of its possibilities to metabolize ammonia.

Sarcopenia becomes in a very useful tool and in the Model for End-Stage Liver Disease (MELD) should include this new item as a way to assess the nutritional and functional status of cirrhotic patients. Montano-Loza et al\[[@B19]\] used for skeletal muscle evaluation computed tomography and they conclude that sarcopenia is associated with improved prediction of mortality in patients with cirrhosis, primarily in patients with low MELD scores. In hospitalized cirrhotic patients there is a correlation between protein malnutrition and sepsis\[[@B20]\].

Montano-Loza et al\[[@B19]\] sustain that the muscle mass and malnutrition is not taken into account in MELD and Child-Pugh scores. So, there is no possibilities to reflect these important features in prognosis of mortality parameters, risks associated with low muscle mass.

So it could be regarded that sarcopenia and cirrhosis has a very related pathogenesis so that simple dietary interventions are insufficient. Efforts should focus on improved understanding of the multiple mechanisms triggered in chronic liver disease, the overlap of the different pathogenesis involved, to arrive to the development of more effective therapies. Sarcopenia is present in almost one third of patients with HCC\[[@B21]\], and constitutes a strong and independent risk factor for mortality. Our results highlight the importance of body composition assessment in clinical practice.

Myostatin is a potent autocrine growth inhibitor produced by myocytes that inhibits skeletal muscle growth and reduces muscle mass in cirrhosis. Qiu et al\[[@B22]\] showed that exposure of mouse skeletal muscle myotubes in culture to ammonium acetate caused a time and concentration-dependent increase in myostatin mRNA and protein expression. They found that hyperammonemia-activated transcription factor p65 NF-κB who binds to the myostatin promoter with transcriptional up regulation. They also found that myotube diameter was significantly greater in the NF-κB knockdown cells compared with the control cells, further supporting their proposal that NF-κB regulates myostatin expression during hyperammonemia. Their observations show that hyperammonemia induces myostatin expression in myotubes *via* an NF-κB-dependent pathway\[[@B16],[@B22],[@B23]\].

In our laboratory some new data was registered. PVL rats showed skeletal muscle structural/ultrastructural and functional changes (unpublished data). It has been suggested that ammonia uptake is increased in CLD and that the subsequent increase in GS capacity is a major alternative pathway for ammonia detoxification\[[@B24]\]. Desjardins et al\[[@B25]\] demonstrated in a porto-cava anastomosis model that GS activity was significantly increased as a result of a post-translational modification of the enzyme.

Our results in both, basic biochemical parameters in liver and skeletal muscle conventional microscopy observation, showed no differences when compared with the control group.

Despite these disappointing results, the fact is that the loss of skeletal muscle is nearly universal in cirrhosis and that adversely affects survival, inducing the development of other complications, and that negatively affects outcome after liver transplantation, decreasing quality of life. However, a reduction in skeletal muscle protein synthesis alone is not sufficient to account for continued reduction in muscle mass in cirrhosis, and an increase in proteolysis is necessary. On the other side cirrhosis is a state of accelerated starvation and the enhanced muscle metabolism may serve as a source of essential amino acids for critical cellular function.

When does skeletal muscle damage start?
---------------------------------------

There is not a complete answer, but to date the loss of skeletal muscle is associated with advanced stages cirrhotic.

The high-resolution optical microscopy (HROM) and transmission electron microscopy in the MHE showed surprising results. The skeletal muscle Triad showed in the dark cell, extensive convergent structure resembling the streets on a map. These membrane systems increased by altering the fibrillar surface structure generating a serious focal damage (Figure [2](#F2){ref-type="fig"}). Immunohistochemistry (PCNA, TUNEL, GS), ROS and mitochondrial respiration measure, supports the HROM and MET findings.
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These results disaggregate the fact that it may not be absolutely necessary a damaged liver, perhaps hyperammonemia alone could trigger the damage in skeletal muscle, somehow independent of liver damage (Figure [2](#F2){ref-type="fig"}).

GUT AND MHE
===========

Is gut involved in MHE pathophysiology?
---------------------------------------

Gut is the major GLN consumer and ammonia producer organ in the body. Ammonia generation derives from the consumption of GLN and glutamate as the most important oxidative fuel for enterocytes and colonocytes\[[@B26]\]. In Gut epithelial cells, these aminoacids have several roles, *i.e*., represents substrates for another amino acids synthesis\[[@B27]\], oxidative fuel\[[@B28]\], nucleotide and nucleic acid synthesis\[[@B29]\], glutathione production\[[@B30]\], amino sugars, NAD^+^, N-acetylglucosamine and N-acetylgalactosamine synthesis, *etc*\[[@B31]\]. GLN administration in patients with different diseases, improved gut function and reduce bacterial translocation, reestablishing normal epithelial permeability\[[@B32],[@B33]\].

Hepatocellular dysfunction due to liver disease, results in an impaired clearance of ammonium and in its inter-organ trafficking\[[@B34],[@B35]\]. Besides acute or chronic liver failure, specific genetic disorders are also characterized by hyperammonemia accompanied by liver and brain disorders with different degrees of severity. Intestinal bacteria, also can represent and extra source of ammonia production. The most relevant bacteria are those with urease enzyme such as enterobacteriaceae. In cirrhosis, small intestinal bacterial overgrowth (SIBO)\[[@B36]\] and dysbiosis\[[@B37],[@B38]\] can be observed. This modification in gut microbiota is produced for various circumstances. First, gut motility is reduced, and acid gastric secretion in stomach is reduced as a consequence of gastric enteropathy, both phenomena influence SIBO\[[@B39]\]. Moreover, an impairment in bile acids production and secretion by the damaged liver was demonstrated\[[@B37]\]. The amount and the profile modification of bile acids are due a reduction in secondary fecal bile acids, a bacteriostatic compound. Another factor involve on SIBO development in cirrhosis, is the alteration in local immunological system, mediated by a low cellular and humoral components of gut immune system\[[@B39]\]. SIBO generates an increase in ammonia gut production, generating an active role of gut in the predisposition in HE development.

In addition of ammonia generation, luminal bacteria can generate other substances such as phenols, mercaptans, benzodiazepine-like compounds and short and medium chain fatty acids, also implicated in pathogenesis of HE\[[@B40]\] exerting a synergic effect on CNS alteration, by modulating the synaptic processes. For example, the neurosteroid allopregnenolone is elevated in patients with HE. This steroid can enhance the effects of GABA on its specific receptors (mainly in GABA-A), increasing it neurodepressive function\[[@B41]\]. On the other hand, endogenous benzodiazepines produced by intestinal bacteria, can augment the opening time of GABA-A receptor after its interaction. The levels of this benzodiazepine like compounds are also elevated in blood of HE patients, exerting a potentiation effect with neurosteroids named before\[[@B42]-[@B44]\].

When gut was evaluated in the PVL distal ileum showed impaired contractile response to acetylcholine and potassium chloride, and reduced expression of proteins markers of occlusive and adherents junctions, such as Zonulin 1 and B catenine, respectively. Also, a reduction in number of cells related with mucosal immune system was observed and altered L-Citrulline was recorded (data not published). All these findings suggest an active role of gut in the development of MHE in a PVL model.

CONCLUSION
==========

This review tries to approach the early stages of the MHE, where even though there are no clinical manifestations, there is evidence of morphological ultrastructural alterations that are present even in the absence of hepatic failure. From this it can be hypothesized that it might not be necessary to have a clinically assessed liver damage to trigger skeletal muscle pathology and maybe it can be started by hyperammonemic condition by itself.

Regarding the gastrointestinal tract, an increase in gut epithelial permeability, alteration in motility and immunological local status were described, generating a predisposition for future complications. Concomitantly, an inespecific inflammatory infiltration is considered guilty of many of the gut impairments of this pathology, followed by mucosal atrophy, edema of lamina propia, fibromuscular proliferation and thickened muscularis mucosa.

In the study of HE, to get close to MHE is to get closer to its big bang; and from here, to travel less transited roads such as skeletal muscle and intestine, is to go even closer. The aim of this review is to expose these roads for further and deeper work.
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